美国代偿期进展性慢性肝病(cACLD)的流行病学:来自2017-2020年国家健康与营养检查调查的见解
该横断面研究分析2017年至2020年3月NHANES数据库中接受瞬时弹性成像的8318名成人,应用Baveno VII肝硬度标准评估cACLD患病率。美国成人cACLD加权患病率为2.4%(95%CI 1.76%-3.03%),可能cACLD为3.46%(95%CI 2.62%-4.3%)。超过85%的cACLD患者不知晓自己患有肝病。
要点
- 美国成人cACLD加权患病率为2.4%(95%CI 1.76%-3.03%),可能cACLD为3.46%(95%CI 2.62%-4.3%)。
- 超过85%的cACLD患者不知晓自己患有肝病。
- cACLD患者中65.9%为男性,40.8%患糖尿病,81.5%肥胖,67.1%患高血压。
核心结论
- cACLD患者多数为男性、糖尿病和肥胖。
- 高不知晓率强调需要加强筛查和监测策略以改善早期发现和管理。
研究设计与样本
- 横断面研究,分析2017年至2020年3月NHANES数据库中接受瞬时弹性成像的成人。
- 应用Baveno VII肝硬度标准:<10 kPa排除,10-15 kPa提示,≥15 kPa确诊cACLD。
- 使用NHANES样本权重生成代表美国平民非机构化人群的数据,统计分析包括分类变量的χ2检验和连续变量的方差分析。
主要发现
- 8318名有瞬时弹性成像结果的成人中,222例确诊cACLD,312例可能cACLD。
- 美国成人cACLD加权患病率为2.4%(95%CI 1.76%-3.03%),可能cACLD为3.46%(95%CI 2.62%-4.3%)。
- 超过85%的cACLD患者不知晓自己患有肝病。
- cACLD患者中65.9%为男性,40.8%患糖尿病,81.5%肥胖,67.1%患高血压。
- cACLD患者中代谢功能障碍相关脂肪性肝病、过量饮酒、丙型肝炎和乙型肝炎的患病率分别为61%、12%、7.1%和0.9%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Compensated advanced chronic liver disease (cACLD) encompasses advanced fibrosis and cirrhosis in asymptomatic patients at risk of developing clinically significant portal hypertension. Patients having cACLD are at high risk of decompensation and liver-related mortality and hence require further evaluation. Due to limited epidemiologic data on cACLD, we aimed to assess its prevalence in the United States (U.S.). METHODS: We performed a cross-sectional study analyzing adults who underwent transient elastography using the National Health and Nutrition Examination Survey (NHANES) database from 2017 to March 2020. The Baveno VII's liver stiffness measurement criteria were applied: <10 kPa to rule out, 10 to 15 kPa as suggestive, and ≥15 kPa to confirm cACLD. NHANES sample weights were used to produce data that is representative of the civilian, noninstitutionalized U.S. population, and statistical analysis included χ2 tests for categorical variables and analysis of variance for continuous variables. RESULTS: Among 8318 adults with transient elastography results, 222 had cACLD, and 312 had possible cACLD. The weighted prevalence of cACLD among U.S. adults was 2.4% (95% confidence interval, 1.76%-3.03%), and that of possible cACLD was 3.46% (95% confidence interval, 2.62%-4.3%). More than 85% of patients with cACLD were unaware that they had liver disease. Among patients with cACLD, 65.9% were males, 40.8% were diabetic, 81.5% were obese, and 67.1% had hypertension. In patients with cACLD, the prevalence of metabolic dysfunction-associated steatotic liver disease, excessive alcohol use, hepatitis C, and hepatitis B was 61%, 12%, 7.1%, and 0.9%, respectively. CONCLUSIONS: Approximately 5 million people in the U.S. may have cACLD, and another 8 million may have possible cACLD. The majority of patients with cACLD tend to be male, diabetic, and obese. The high rate of unawareness underscores the need for enhanced screening and surveillance strategies to improve early detection and management.
引用
- Goyal RM, Doshi A, Rao S, et al. Epidemiology of Compensated Advanced Chronic Liver Disease (cACLD) in the United States: Insights From the National Health and Nutrition Examination Survey, 2017-2020. Clin Gastroenterol Hepatol. 2025. PMID: 40581070. doi:10.1016/j.cgh.2025.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。